The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...

Just a few weeks into the full-scale rollout of its Omnipod 5 insulin pump, Insulet has gotten the green light to expand the device’s reach even further. When the FDA originally cleared the automated, ...

Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation's Omnipod 5 Automated Insulin Delivery System ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it has ...

Insulet (PODD) announced an update on their ongoing clinical study. Study Overview: Insulet Corporation is running a new clinical study titled “An Evaluation of the Omnipod® M System in Adults With ...

ORLANDO -- Putting type 2 diabetes patients on an automated insulin delivery (AID) pump improved glycemic control, the SECURE-T2D pivotal trial showed. Type 2 diabetes patients started on the Omnipod ...

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked ...